Personalized Ventilation Strategies: Advancing Individualized Respiratory Care in Critical Illness

Abstract

Personalized ventilation strategies represent an evolution in critical care medicine, focusing on tailoring mechanical ventilation parameters to the individual patient's physiology and disease characteristics. Recent advances in the understanding of ventilator-induced lung injury (VILI), heterogeneous lung pathophysiology, and molecular biomarkers have catalyzed the shift from traditional one-size-fits-all approaches to precision-guided respiratory support. This review summarizes the epidemiological significance, pathophysiological rationale, clinical manifestations, diagnostic considerations, and therapeutic strategies underpinning personalized ventilation. Further, it discusses emerging evidence, guideline recommendations, and clinical implications for optimizing outcomes in patients with acute respiratory failure, particularly those with acute respiratory distress syndrome (ARDS) and other complex pulmonary disorders.

Introduction

Mechanical ventilation remains a cornerstone of supportive care in intensive care units (ICUs) worldwide. However, uniform ventilation settings may not account for patient-specific factors such as lung compliance, recruitability, and comorbid conditions, potentially leading to suboptimal outcomes or iatrogenic harm. The paradigm of personalized ventilation aims to mitigate these risks by adapting ventilatory support to the unique pathophysiological profile of each patient. This approach integrates advanced monitoring, imaging, and molecular diagnostics to refine ventilator settings, minimize VILI, and improve survival. The following sections provide an in-depth analysis of the epidemiology, mechanisms, and current evidence guiding the implementation of personalized ventilation strategies in clinical practice.

Epidemiology / Disease Burden

Respiratory failure requiring mechanical ventilation is a major cause of morbidity and mortality in ICUs, affecting millions of patients annually. ARDS, a syndrome characterized by severe hypoxemia and non-cardiogenic pulmonary edema, occurs in approximately 10% of ICU admissions and is associated with mortality rates ranging from 30% to 45%. Traditional ventilation approaches, although life-saving, contribute to secondary lung injury in a significant proportion of patients due to overdistension, cyclic atelectasis, and ventilator asynchrony. The heterogeneity in patient response to ventilation underscores the need for individualized strategies to reduce complications and optimize resource utilization, especially in the context of surges such as the COVID-19 pandemic.

Pathophysiology

The pathophysiological basis for personalized ventilation lies in the diversity of lung pathology seen in critical illness. The mechanisms of VILI include barotrauma, volutrauma, atelectrauma, and biotrauma, each exacerbated by inappropriate ventilator settings. Lung recruitability, regional compliance, and the spatial distribution of injury vary widely among patients and even within the same lung. Biomarkers such as interleukin-6, surfactant proteins, and imaging modalities like electrical impedance tomography (EIT) and lung ultrasound provide insights into dynamic lung mechanics, facilitating real-time adjustments in ventilation. Personalized strategies aim to optimize gas exchange, minimize stress and strain, and preserve lung tissue, thereby reducing inflammation and multisystem organ dysfunction.

Risk Factors

Several factors increase the risk of adverse outcomes during mechanical ventilation, including advanced age, pre-existing lung disease (such as COPD or interstitial lung disease), obesity, high driving pressures, and severe hypoxemia. Genetic predispositions, comorbidities (e.g., diabetes, cardiac disease), and the underlying etiology of respiratory failure also influence individual susceptibility to VILI. Additionally, factors such as delayed recognition of ARDS, inadequate monitoring, and insufficient staffing further amplify the risks. Understanding these risk profiles is critical for tailoring ventilation strategies and implementing preventive interventions.

Clinical Features

Patients requiring personalized ventilation often present with severe hypoxemia, increased work of breathing, and heterogeneous lung involvement on imaging studies. Clinical features may include dyspnea, tachypnea, use of accessory muscles, and signs of respiratory distress. In ARDS, hallmark findings include diffuse bilateral infiltrates, reduced lung compliance, and impaired oxygenation refractory to standard supportive measures. Ventilator-patient asynchrony, high plateau pressures, and poor response to conventional ventilation settings are clinical cues indicating the need for individualized approaches. Monitoring for signs of VILI, such as subcutaneous emphysema, pneumothorax, or worsening gas exchange, is pivotal for timely intervention.

Diagnosis

Diagnosis of respiratory failure requiring personalized ventilation involves integrated clinical assessment, laboratory testing, and advanced imaging. Arterial blood gases, chest radiography, computed tomography (CT), and point-of-care ultrasound are routinely employed to characterize the extent and distribution of lung injury. Lung mechanics are quantified using static and dynamic compliance measurements, driving pressure, and pressure-volume curves. EIT, esophageal manometry, and transpulmonary pressure monitoring offer bedside tools for assessing recruitability and guiding titration of PEEP (positive end-expiratory pressure). Biomarkers and genomics are increasingly being explored to further stratify patients and predict response to specific ventilation strategies.

Treatment & Management

Personalized ventilation encompasses a spectrum of interventions tailored to patient-specific physiology. Low tidal volume ventilation (4-8 mL/kg predicted body weight) remains foundational, but is further refined by adjusting PEEP, driving pressure, and respiratory rate based on individual mechanics. Recruitment maneuvers, prone positioning, and neuromuscular blockade are selectively employed in refractory hypoxemia, guided by real-time monitoring. Adjunctive therapies include extracorporeal membrane oxygenation (ECMO) for severe cases and lung-protective strategies such as limiting inspiratory pressures and minimizing oxygen toxicity. Sedation, weaning protocols, and early mobilization are integrated into holistic care plans to optimize functional recovery.

Recent Advances / Emerging Therapies

Recent advances in personalized ventilation include the utilization of EIT for regional ventilation monitoring, closed-loop ventilator systems with automated algorithm-based adjustments, and machine learning models predicting individual response to ventilatory interventions. The development of molecular phenotyping and precision biomarkers enables stratification of ARDS subtypes, facilitating targeted therapies. Integration of artificial intelligence (AI)-driven decision support tools and telemedicine platforms further enhances the scalability of personalized approaches. Ongoing clinical trials are evaluating novel interventions such as personalized PEEP titration, variable ventilation modes, and the use of inhaled biologics to modulate inflammation.

Guideline Recommendations

International guidelines, including those from the Surviving Sepsis Campaign and the American Thoracic Society, endorse lung-protective ventilation as standard of care for ARDS, emphasizing low tidal volumes and individualized PEEP strategies. Recent updates advocate for the use of advanced monitoring (e.g., driving pressure, EIT) to inform personalized settings. Prone positioning is recommended in moderate-to-severe ARDS unresponsive to conventional therapy. Guidelines also highlight the importance of multidisciplinary care, regular reassessment, and early involvement of specialized respiratory teams. Personalized protocols are increasingly recognized as essential for optimizing outcomes and reducing healthcare costs.

Conclusion

The transition toward personalized ventilation strategies marks a significant advance in the management of acute respiratory failure. By integrating patient-specific data, advanced monitoring, and precision medicine principles, clinicians can optimize mechanical ventilation, minimize complications, and improve survival in critically ill patients. Ongoing research, technological innovation, and guideline refinement will continue to drive the evolution of individualized respiratory care, ensuring that ventilation strategies are tailored to the unique needs of each patient in the ICU setting.